SEATTLE and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development ...

Achieve Life Sciences, Inc. has submitted a New Drug Application (NDA) to the U.S. FDA for cytisinicline, which, if approved, would be the first new pharmacotherapy for nicotine dependence in 20 years ...

IQWiG has now published its final benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation, also in combination with each other, compared with no drug therapy.

IQWiG has now published its final benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation, also in combination with each other, compared with no drug therapy.

Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on ...

New research from the University of Missouri School of Medicine suggests there may be another way to treat cigarette cravings. Researchers found that theta-burst transcranial magnetic stimulation (TBS ...

They recruited 443 smokers to receive five telephone counseling sessions and nicotine replacement therapy by mail for four weeks, and then randomly assigned patients to one of two treatment groups: ...

Patients with chronic obstructive pulmonary disease (COPD) who smoke were less likely to receive tobacco dependence treatment (TDT) if they lived in rural areas or had longer travel times to care, ...

Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non–Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 PURPOSE: There is a current lack of ...